curasan AG takes over dental company with innovative technology

DGAP-News: curasan AG / Key word(s): Takeover

03.07.2019 / 20:16

The issuer is solely responsible for the content of this announcement.


– Company acquisition successfully completed

– Minimal-invasive treatment system for implantologists

– Ideal expansion of curasan product range as solution provider

Kleinostheim, 3 July 2019 – curasan AG, Germany, (ISIN old: DE0005494538 / new since 3 July 2019: DE000A2YPGM4), a leading specialist for medical products in the field of orthobiologics, has now successfully completed the acquisition of a dental company announced at the end of January as part of its strategic realignment. The parties have agreed confidentiality on the purchase price.

The acquired company is JEDER GmbH, Dental Technology, Klosterneuburg/Vienna, Austria, which developed the innovative JEDER-system for implantologists.

With the help of the JEDER-system, a sinus lift in the upper jaw – otherwise a “dreaded” surgery – can be performed in an easy and almost painless manner. The procedure is completely minimally invasive for patients, without incision or suture.This gives the JEDER-system a convincing unique selling point in the market.

“The JEDER-System is a surgical device with economically attractive disposables – an ideal complement to our product range for dental implantology”, explains Michael Schlenk, CEO of curasan AG. “This will result in interesting cross-selling possibilities regarding our CERASORB Paste, which is perfectly suited for the combined use with the JEDER-system. “

“The treatment method associated with the JEDER-system is regarded by experts as a future global standard procedure for the minimal-invasive sinus lift,” outlines Gregor Siebert, Head of Marketing and Sales at curasan AG.

“The technology has great future potential; it opens new markets for us and is a helpful door-opener at doctors and clinics we did not serve up to now. Furthermore, the simplicity of use offers also less experienced dentists access to this group of patients.”

The product package consists of a bone drill, pump and tubeset and has a CE-certification. Thus, it can be marketed in Europe straightaway. It is also listed in the US. Moreover, there is patent protection for various components in China, India and other countries.

Contact curasan AG:
Andrea Weidner
Investor Relations &
Corporate Communications
+49 6027 40 900-51
ir@curasan.com

About curasan AG:
curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan. curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in Wake Forest, near Raleigh, N.C., USA. curasan’s innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange.


03.07.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: curasan AG
Lindigstraße 4
63801 Kleinostheim
Germany
Phone: 06027/40 900 0
Fax: 06027/40 900 29
E-mail: info@curasan.de
Internet: www.curasan.de
ISIN: DE000A2YPGM4
WKN: A2YPGM
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 835883

 
End of News DGAP News Service

show this